TED Talks Daily

Podbit · TED Talks Daily

Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech

Explore episode Jun 26, 2026
Health & Fitness
The Dark Side of Moderation Molecules: Anhedonia Risk

Can Ozempic end addiction? | Dhruv Khullar | Your Body on T… · Jun 26, 2026 Health & Fitness

For some patients, GLP-1s don't just moderate desire — they appear to extinguish it. Reports of anhedonia (inability to feel pleasure) and blunted mood raise serious questions about psychological side effects that remain poorly studied. A drug that makes you not care about anything is not the same as one that helps you care less about the wrong things.

Where this was said

Dhruv Khullar's TED Talk: GLP-1s and the Science of Addiction

At 10:37 · chapter starts 5:29

The centerpiece of the episode, Khullar's TED Talk opens with Mary — a patient who had failed rehab, AA, and Antabuse before enrolling in an Ozempic clinical trial and achieving sobriety. From there, Khullar unfolds the drug's origin story: discovered in the 1980s but unworkable until a Gila monster researcher found a peptide in lizard venom that lasted hours rather than minutes. That discovery unlocked a class of drugs now showing effects far beyond digestion — specifically in the brain's mesolimbic reward pathway. GLP-1s appear to blunt dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. One neuroscientist told Khullar this suggests addiction may have a single universal pathology. But Khullar urges caution: these 'moderation molecules' can become desire dampeners, and anhedonia is a real risk. He closes by invoking Aristotle — and then dismantling him: Aristotle never faced Doritos, TikTok, or fentanyl. Moderation today isn't just a virtue; it is, the science suggests, a physiological state.

Health & Fitness
Mary's Story: How Ozempic Cleared Her Alcohol Noise

Can Ozempic end addiction? | Dhruv Khullar | Your Body on T… · Jun 26, 2026 Health & Fitness

Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the craving was gone. She stopped drinking, lost 55 pounds, ended a bad relationship, and started exercising. GLP-1s didn't just treat her addiction; they gave her room to rebuild her life.

Health & Fitness
The Universal Addiction Pathway: One Molecule to Rule Them All?

Can Ozempic end addiction? | Dhruv Khullar | Your Body on T… · Jun 26, 2026 Health & Fitness

GLP-1s don't just reduce appetite — they appear to dampen dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. A neuroscientist told Khullar this suggests addiction has a single universal pathology, and GLP-1s may be part of how we fix it.

Similar podbits

Health & Fitness
Anxiety Is the Dizziness of Freedom — Not Fear

Finding Your Life Path, Solved · Sep 2, 2026 Health & Fitness

Anxiety is not fear. Fear has an object — a wolf, a threat. Anxiety is the vertigo of standing at the edge of infinite possibility and knowing that choosing any one thing closes off all the others. Kierkegaard argued that the depth of your anxiety is proportional to the depth of your potential.

Health & Fitness
AI in Healthcare: Where It Helps and Where It Doesn't

Using AI to Increase Your Intelligence & Enrich Humanity | … · Aug 10, 2026 Health & Fitness

AI nailed Andrew Huberman's vertigo-vs-low-blood-pressure diagnosis because that pattern has been reported millions of times. But every patient's liver is different and data on liver surgeries is scarce worldwide — making solo robot surgery dangerous. The rule is simple: data abundance means AI can help; data scarcity means keep the human in the loop.